ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.

Andrea Wang-Gillam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.